Prolonged effects of adenoviral vector priming on T-cell cytokine production in heterologous adenoviral vector/mRNA COVID-19 vaccination regimens
Abstract mRNA and adenoviral vector vaccine platforms were used for the primary series of COVID-19 vaccines in many countries. However, the distinct immunogenic properties on these platforms remain less understood. We traced neutralizing antibodies, memory B cells, and T cells longitudinally in coho...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-05-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-025-00054-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850231317810118656 |
|---|---|
| author | Masanori Isogawa Taishi Onodera Akira Ainai Ryutaro Kotaki Takayuki Kanno Shinji Saito Minoru Tobiume Kenzo Tokunaga Megumi Hara Yoshio Hirota Tadaki Suzuki Yoshimasa Takahashi Tomomi Tsuru |
| author_facet | Masanori Isogawa Taishi Onodera Akira Ainai Ryutaro Kotaki Takayuki Kanno Shinji Saito Minoru Tobiume Kenzo Tokunaga Megumi Hara Yoshio Hirota Tadaki Suzuki Yoshimasa Takahashi Tomomi Tsuru |
| author_sort | Masanori Isogawa |
| collection | DOAJ |
| description | Abstract mRNA and adenoviral vector vaccine platforms were used for the primary series of COVID-19 vaccines in many countries. However, the distinct immunogenic properties on these platforms remain less understood. We traced neutralizing antibodies, memory B cells, and T cells longitudinally in cohorts that received either mRNA (BNT162b2 or mRNA-1273) or adenoviral vector (ChAdOx1) vaccines with homologous or heterologous regimens (total 9 groups, n = 26–28 for each group) at 4 weeks interval. The priming and boosting effects on various immune parameters were comparably assessed between mRNA and adenoviral vector platforms. We found that initial priming by adenoviral vector vaccine elicited robust T cell responses, but B cell responses, including antibody titers, were relatively lower than those elicited by mRNA priming. The dissociation between T cell and antibody responses were exaggerated at greater extents after the homologous booster with the adenoviral vector vaccine, resulting in 5-19-fold lower antibody titers despite comparable spike-specific T cell numbers at day 28 after the boost. Robust IFN-γ and few IL-2 and IL-5 production characterized T cell functionality primed by adenoviral vector. Boosting with mRNA vaccines restored their IL-2 and IL-5 production at some extents, but the IL-5 T cell responses elicited by adenoviral vector/mRNA heterologous regimen waned faster than those by mRNA homologous regimen. Thus, our data revealed that the cytokine production of helper T cells was skewed by adenoviral vector priming, leading to the attenuated IL-2 and IL-5 responses which were prolonged even after mRNA boosting, suggesting an imprinting of T-cell functionality depending on the vaccine platform used for initial priming. These results highlight the importance of selecting vaccine platforms based on the immunogenic properties. |
| format | Article |
| id | doaj-art-5b9022ec7eb44ac2afec958b405d85dd |
| institution | OA Journals |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-5b9022ec7eb44ac2afec958b405d85dd2025-08-20T02:03:35ZengNature PortfolioScientific Reports2045-23222025-05-0115111110.1038/s41598-025-00054-xProlonged effects of adenoviral vector priming on T-cell cytokine production in heterologous adenoviral vector/mRNA COVID-19 vaccination regimensMasanori Isogawa0Taishi Onodera1Akira Ainai2Ryutaro Kotaki3Takayuki Kanno4Shinji Saito5Minoru Tobiume6Kenzo Tokunaga7Megumi Hara8Yoshio Hirota9Tadaki Suzuki10Yoshimasa Takahashi11Tomomi Tsuru12Research Center for Vaccine Development, National Institute of Infectious Diseases, Japan Institute for Health SecurityResearch Center for Vaccine Development, National Institute of Infectious Diseases, Japan Institute for Health SecurityDepartment of Infectious Disease Pathology, National Institute of Infectious Diseases, Japan Institute for Health SecurityResearch Center for Vaccine Development, National Institute of Infectious Diseases, Japan Institute for Health SecurityDepartment of Infectious Disease Pathology, National Institute of Infectious Diseases, Japan Institute for Health SecurityDepartment of Infectious Disease Pathology, National Institute of Infectious Diseases, Japan Institute for Health SecurityDepartment of Infectious Disease Pathology, National Institute of Infectious Diseases, Japan Institute for Health SecurityDepartment of Infectious Disease Pathology, National Institute of Infectious Diseases, Japan Institute for Health SecurityDepartment of Preventive Medicine, Faculty of Medicine, Saga UniversityClinical Epidemiology Research Center, SOUSEIKAI Medical Group (Medical Co. LTA)Department of Infectious Disease Pathology, National Institute of Infectious Diseases, Japan Institute for Health SecurityResearch Center for Vaccine Development, National Institute of Infectious Diseases, Japan Institute for Health SecurityPS Clinic, SOUSEIKAI Medical Group (Medical Co. LTA)Abstract mRNA and adenoviral vector vaccine platforms were used for the primary series of COVID-19 vaccines in many countries. However, the distinct immunogenic properties on these platforms remain less understood. We traced neutralizing antibodies, memory B cells, and T cells longitudinally in cohorts that received either mRNA (BNT162b2 or mRNA-1273) or adenoviral vector (ChAdOx1) vaccines with homologous or heterologous regimens (total 9 groups, n = 26–28 for each group) at 4 weeks interval. The priming and boosting effects on various immune parameters were comparably assessed between mRNA and adenoviral vector platforms. We found that initial priming by adenoviral vector vaccine elicited robust T cell responses, but B cell responses, including antibody titers, were relatively lower than those elicited by mRNA priming. The dissociation between T cell and antibody responses were exaggerated at greater extents after the homologous booster with the adenoviral vector vaccine, resulting in 5-19-fold lower antibody titers despite comparable spike-specific T cell numbers at day 28 after the boost. Robust IFN-γ and few IL-2 and IL-5 production characterized T cell functionality primed by adenoviral vector. Boosting with mRNA vaccines restored their IL-2 and IL-5 production at some extents, but the IL-5 T cell responses elicited by adenoviral vector/mRNA heterologous regimen waned faster than those by mRNA homologous regimen. Thus, our data revealed that the cytokine production of helper T cells was skewed by adenoviral vector priming, leading to the attenuated IL-2 and IL-5 responses which were prolonged even after mRNA boosting, suggesting an imprinting of T-cell functionality depending on the vaccine platform used for initial priming. These results highlight the importance of selecting vaccine platforms based on the immunogenic properties.https://doi.org/10.1038/s41598-025-00054-x |
| spellingShingle | Masanori Isogawa Taishi Onodera Akira Ainai Ryutaro Kotaki Takayuki Kanno Shinji Saito Minoru Tobiume Kenzo Tokunaga Megumi Hara Yoshio Hirota Tadaki Suzuki Yoshimasa Takahashi Tomomi Tsuru Prolonged effects of adenoviral vector priming on T-cell cytokine production in heterologous adenoviral vector/mRNA COVID-19 vaccination regimens Scientific Reports |
| title | Prolonged effects of adenoviral vector priming on T-cell cytokine production in heterologous adenoviral vector/mRNA COVID-19 vaccination regimens |
| title_full | Prolonged effects of adenoviral vector priming on T-cell cytokine production in heterologous adenoviral vector/mRNA COVID-19 vaccination regimens |
| title_fullStr | Prolonged effects of adenoviral vector priming on T-cell cytokine production in heterologous adenoviral vector/mRNA COVID-19 vaccination regimens |
| title_full_unstemmed | Prolonged effects of adenoviral vector priming on T-cell cytokine production in heterologous adenoviral vector/mRNA COVID-19 vaccination regimens |
| title_short | Prolonged effects of adenoviral vector priming on T-cell cytokine production in heterologous adenoviral vector/mRNA COVID-19 vaccination regimens |
| title_sort | prolonged effects of adenoviral vector priming on t cell cytokine production in heterologous adenoviral vector mrna covid 19 vaccination regimens |
| url | https://doi.org/10.1038/s41598-025-00054-x |
| work_keys_str_mv | AT masanoriisogawa prolongedeffectsofadenoviralvectorprimingontcellcytokineproductioninheterologousadenoviralvectormrnacovid19vaccinationregimens AT taishionodera prolongedeffectsofadenoviralvectorprimingontcellcytokineproductioninheterologousadenoviralvectormrnacovid19vaccinationregimens AT akiraainai prolongedeffectsofadenoviralvectorprimingontcellcytokineproductioninheterologousadenoviralvectormrnacovid19vaccinationregimens AT ryutarokotaki prolongedeffectsofadenoviralvectorprimingontcellcytokineproductioninheterologousadenoviralvectormrnacovid19vaccinationregimens AT takayukikanno prolongedeffectsofadenoviralvectorprimingontcellcytokineproductioninheterologousadenoviralvectormrnacovid19vaccinationregimens AT shinjisaito prolongedeffectsofadenoviralvectorprimingontcellcytokineproductioninheterologousadenoviralvectormrnacovid19vaccinationregimens AT minorutobiume prolongedeffectsofadenoviralvectorprimingontcellcytokineproductioninheterologousadenoviralvectormrnacovid19vaccinationregimens AT kenzotokunaga prolongedeffectsofadenoviralvectorprimingontcellcytokineproductioninheterologousadenoviralvectormrnacovid19vaccinationregimens AT megumihara prolongedeffectsofadenoviralvectorprimingontcellcytokineproductioninheterologousadenoviralvectormrnacovid19vaccinationregimens AT yoshiohirota prolongedeffectsofadenoviralvectorprimingontcellcytokineproductioninheterologousadenoviralvectormrnacovid19vaccinationregimens AT tadakisuzuki prolongedeffectsofadenoviralvectorprimingontcellcytokineproductioninheterologousadenoviralvectormrnacovid19vaccinationregimens AT yoshimasatakahashi prolongedeffectsofadenoviralvectorprimingontcellcytokineproductioninheterologousadenoviralvectormrnacovid19vaccinationregimens AT tomomitsuru prolongedeffectsofadenoviralvectorprimingontcellcytokineproductioninheterologousadenoviralvectormrnacovid19vaccinationregimens |